Nivolumab (Nivo) vs investigator’s choice (IC) for platinum-refractory (PR) recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN; Checkmate 141): Outcomes in first-line (1L) R/m patients and updated safety and efficacy.
Year: 2017
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Maura L. Gillison, George R. Blumenschein, Jérôme Fayette, Joel Guigay, A. Dimitrios Colevas, Lisa Licitra, Kevin Harrington, Stefan Kasper, Everett E. Vokes, Caroline Even, Francis P. Worden, Nabil F. Saba, Lara Carmen Iglesias Docampo, Robert I. Haddad, Tamara Rordorf, Naomi Kiyota, Makoto Tahara, Mark John Lynch, Justin Kopit, Robert L. Ferris
Institutions: The Ohio State University, The University of Texas MD Anderson Cancer Center, Centre Léon Bérard, Centre Antoine Lacassagne, Stanford University, University of Milan, Fondazione IRCCS Istituto Nazionale dei Tumori, Royal Marsden NHS Foundation Trust, Institute of Cancer Research, Essen University Hospital, University of Chicago Medical Center, Institut Gustave Roussy, University of Michigan, Winship Cancer Institute, Hospital Universitario 12 De Octubre, Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, University Hospital Zurich, Kobe University Hospital, National Cancer Center Hospital East, Bristol-Myers Squibb (United States), University of Pittsburgh Medical Center
Language: English
Topic: Head and Neck Cancer Studies
Subfield: Otorhinolaryngology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2760618652